Drug Approval | December 26, 2023
Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
US FDA approval based on NEURO-TTRansform Phase III results
US FDA approval based on NEURO-TTRansform Phase III results
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Development services for gene and cell therapies is planned to begin first in 2025
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Subscribe To Our Newsletter & Stay Updated
